Free Trial
→ The SpaceX filing is public. The window is closing. (From Behind the Markets) (Ad)tc pixel
NASDAQ:IMMP

Prima BioMed Q2 2026 Earnings Report

Prima BioMed logo
$0.49 +0.01 (+1.77%)
As of 08:57 AM Eastern
ProfileEarnings HistoryForecast

Prima BioMed EPS Results

Actual EPS
-$0.10
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Prima BioMed Revenue Results

Actual Revenue
$1.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Prima BioMed Announcement Details

Quarter
Q2 2026
Date
1/30/2026
Time
Before Market Opens
Conference Call Date
Thursday, January 29, 2026
Conference Call Time
6:00PM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Prima BioMed's Q2 2026 Press ReleasePress Release

Prima BioMed Earnings Headlines

IMMP Shareholder Alert: July 6, 2026 Lead Plaintiff Deadline in Immutep Limited Securities Class Action - Contact The Gross Law Firm
 |  prnewswire.comhttps://www.prnewswire.com/news-releases/immp-shareholder-alert-july-6-2026-lead-plaintiff-deadline-in-immutep-limited-securities-class-action---contact-the-gross-law-firm-302779751.html
Bronstein, Gewirtz & Grossman LLC Urges Immutep Limited Investors to Act: Class Action Filed Alleging Investor Harm
May 25 at 12:00 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/25/3300681/9788/en/bronstein-gewirtz-grossman-llc-urges-immutep-limited-investors-to-act-class-action-filed-alleging-investor-harm.html
The SpaceX filing is public. The window is closing.
SpaceX just filed its S-1. The IPO is confirmed for June 12 - $75 billion, ticker SPCX, potentially the largest in history. The 21-bank syndicate has already locked up shares, so retail investors won't get access. But the S-1 exposed one publicly traded company Musk cannot operate without - and it's still cheap. Dylan Jovine is releasing the ticker free before June 12 changes the price.tc pixel
May 26 at 1:00 AM  |  Behind the Markets (Ad)
IMMP Investors Have Opportunity to Lead Immutep Ltd. Securities Fraud Lawsuit
May 25 at 3:55 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/immp-investors-have-opportunity-to-lead-immutep-ltd-securities-fraud-lawsuit-302780915.html
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP
May 24 at 10:45 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/25/3300496/673/en/rosen-top-ranked-investor-counsel-encourages-immutep-ltd-investors-to-secure-counsel-before-important-deadline-in-securities-class-action-immp.html
IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm
May 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/22/3300203/0/en/immp-investors-have-opportunity-to-lead-immutep-limited-securities-fraud-lawsuit-with-the-schall-law-firm.html
See More Prima BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Prima BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Prima BioMed and other key companies, straight to your email.

About Prima BioMed

Prima BioMed (NASDAQ:IMMP), trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response. This candidate is being evaluated in multiple Phase II clinical trials across a range of solid tumors, including breast and lung cancers.

Founded in 2001 and headquartered in Sydney, Australia, Prima BioMed has built its expertise in immuno-oncology over two decades of research and development. In 2018, the company rebranded as Immutep to reflect its broader strategic focus on LAG-3–based immunotherapies. Since its inception, Prima BioMed has collaborated with leading academic institutions and cancer centers worldwide to advance its clinical programs and validate the therapeutic potential of LAG-3 modulation.

Prima BioMed maintains a global footprint with additional offices and research partnerships in Europe and the United States. Through collaborations with pharmaceutical partners and contract research organizations, the company aims to accelerate clinical development, streamline regulatory submissions and establish a foundation for potential commercialization. Its pipeline also includes monoclonal antibodies targeting LAG-3 and other immune checkpoints, underscoring a commitment to expanding treatment options for patients with hard-to-treat malignancies.

View Prima BioMed Profile
Earnings Tools